LOS ANGELES, CA / ACCESSWIRE / November 24, 2014 / BioSig Technologies (OTCQB: BSGM), a medical device company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to greatly improve the clinical value of cardiac recordings in the $3 billion electrophysiology (EP) marketplace, today announced that its President and CEO Gregory D. Cash will present at the 7th Annual LD Micro Main Event Conference on Thursday, December 4, 2014 at 12:00 p.m. Pacific. The Conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles, California (www.ldmicro.com).
"As a newly public company, we're excited to get in front of investors to educate them about the demand for more effective cardiac technology in the fast-growing EP marketplace, and to discuss our next-generation PURE EP System and strategy for commercialization," said Gregory D. Cash, BioSig President and CEO. "With the Conference being held just up the street from our corporate headquarters, we look forward to meeting with a good mix of growth-oriented investors to include our newer as well as long term shareholders."
Along with Mr. Cash, BioSig Technologies' Executive Chairman Ken Londoner will be available at the Conference for one-on-one meetings with members of the investment community on Thursday, December 4th. Please contact conference organizers ([email protected]) to arrange a meeting.
About BioSig Technologies
BioSig is a medical device company that has developed a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE EP System.
PURE EP is a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets - areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) - making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) approval for the PURE EP System. The Company has already achieved proof of concept validation through UCLA EP & Animal Labs, and is collaborating with several of the nation's most prestigious cardiac arrhythmia centers ranging from UCLA Cardiac Arrhythmia Center to Mayo Clinic in Minnesota.
Forward-Looking Statements
This release includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements.
Investor Contact
Financial Profiles, Inc.
Jody Cain
[email protected]
310.622.8227
Media Contact
Financial Profiles, Inc.
Matt Andrejczak
[email protected]
310.622.8241
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
SOURCE: BioSig Technologies